{
    "2021-11-12": [
        [
            {
                "time": "",
                "original_text": "凯莱英：香港联交所审议公司发行境外上市外资股申请",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "香港联交所",
                        "境外上市",
                        "外资股申请"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "凯莱英(002821.SZ)：香港联交所上市委员会已审阅公司上市申请",
                "features": {
                    "keywords": [
                        "凯莱英",
                        "香港联交所",
                        "上市委员会",
                        "审阅",
                        "上市申请"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药板块2021Q3分析暨11月月报：高基数下增速放缓 板块基本面依旧强劲 把握配置窗口期",
                "features": {
                    "keywords": [
                        "医药板块",
                        "2021Q3",
                        "高基数",
                        "增速放缓",
                        "基本面强劲",
                        "配置窗口期"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【最全】2022年中国医药研发外包(CRO)行业上市公司全方位对比(附业务布局汇总、业绩对比、业务规划等)",
                "features": {
                    "keywords": [
                        "医药研发外包",
                        "CRO",
                        "上市公司",
                        "业务布局",
                        "业绩对比",
                        "业务规划"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}